Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative, according to the authors of a study of the introduction of the infliximab biosimilar CT-P13 in a single hospital in Switzerland. They found no differences in outpatient costs, inpatient costs, and length of hospital stays associated with introduction of the biosimilar.
Image credit: Suteren Studio - stock.adobe.com
The economic impact of non-medical switching is “subject to debate,” the authors said, as many economic evaluations have focused on drug purchase prices alone and have not considered health resource utilization. Costs associated with training medical staff, additional laboratory tests, administrative procedures, potentially switching back to another biologic, additional outpatient visits, and hospital stays may reduce the cost savings from the purchase price of the drug.
Infliximab, a monoclonal antibody targeting tumor necrosis factor (TNF)-α, is used to treat immune-mediated inflammatory diseases. CT-P13 was approved by the European Medicines Agency in 2013 and entered the market in Switzerland in 2016. The retrospective cohort study assessed health care expenditures in Swiss francs (CHF) of patients treated with the reference infliximab or the biosimilar CT-P13, based on outpatient costs, inpatient costs, and length of inpatient stays. Patients with inflammatory autoimmune diseases who were part of a previous retrospective study on reasons for discontinuation of CT-P13 were enrolled from a university hospital in Western Switzerland.
There were seven cohorts including 60 patients in immuno-allergology, 84 in rheumatology and 114 in gastroenterology:
The authors noted a few differences in patient characteristics between cohorts: patients who switched to CT-P13 and back to the originator were older (mean, 54 years) than those who started and discontinued the originator (mean, 34) and patients who started and discontinued CT-P13 (mean, 36). Also there was a higher proportion of female patients in the cohort that started and discontinued the reference product compared to the group that switched from the reference product to CT-P13 and maintained CT-P13.
Overall, inpatient costs were CHF 1,611 (SD, 1,020) per hospital day and outpatient costs were CHF 4,991 (SD, 6,931) per infusion, and the length of stay was 20 (SD, 28) days.
Because of the small sample size, the investigators used bootstrap analyses to compare outpatient and inpatient costs between cohorts: Patients who started and maintained CT-P13 and those who switched from the reference product to CT-P13 and then discontinued CT-P13 had lower mean costs per infusion than patients who switched from the reference product to CT-P13 and maintained CT-P13 and those who switched from the reference product to CT-P13 and back to the reference product. For inpatient costs, the patients who started then discontinued CT-P13 had a lower mean cost per hospital day than those who started and maintained the reference product.
The authors reported that multivariable analysis showed differences in both outpatient and inpatient costs by disease category, with rheumatology patients having higher mean cost per infusion than patients in gastroenterology or immuno-allergology. Patients in rheumatology and immuno-allergology had higher mean costs per inpatient hospital day than patients in gastroenterology. However, the authors noted that age was positively associated with costs, and patients in gastroenterology tended to be younger in their cohorts.
Length of stay was significantly different between some cohorts: patients who started then discontinued CT-P13 had shorter hospital stays compared to those who started then discontinued the reference product and those who started and maintained CT-P13.
The authors concluded that the introduction of CT-P13 in this hospital and any associated disruption of treatment management were not associated with differences in average outpatient costs, inpatient costs, or length of stay. They called for further research to evaluate the cost-effectiveness and benefits to patients associated with non-medical switching policies.
Reference
Krstic M, Devaud JC, Sadeghipour F, Marti J. Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data. Health Econ Rev. 2024;14(1):31. doi:10.1186/s13561-024-00507-5
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 21st 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors
August 15th 2024An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.
AI and Biosimilars: Bridging Global Health Disparities and Enhancing Treatment Efficiency
August 10th 2024Artificial intelligence (AI) technologies can support global health systems in integrating biosimilars into care models, reducing health care costs, enhancing treatment decision-making strategies, and narrowing the gap between high-income and low- and middle-income countries.